2020

- Bausch Health’s Perspective on COVID-19 (Coronavirus)

- Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic

2019

- Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

- Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting

- Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease

- Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis

- Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.

2018

- Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

- Salix to Present Clinical Data for XIFAXAN^® (RIFAXIMIN) and PLENVU^® at the American College of Gastroenterology Annual Meeting

- Salix Resolves Legacy SEC Investigation With No Penalty

- Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET^® (Avatrombopag)

- Bausch Health Announces Resolution Of XIFAXAN^® Intellectual Property Litigation

- Salix Announces U.S. Launch of PLENVU^®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies

- US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA^™ (lofexidine) At 2018 PAINWeek Conference

- US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA^™ (lofexidine) 0.18 Mg Tablets

- Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

- Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA^™ (lofexidine)

- Salix To Highlight New Clinical Data During Digestive Disease Week

- Salix Receives FDA Approval For PLENVU^®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies

- Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR^® Injection

- Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

- Salix Launches ‘Let’s Talk 2’ IBS Awareness Campaign

- Salix provides update on FDA submission for PLENVU^®*

2017

- Salix Announces Filing Acceptance For Plenvu^®* Next Generation Bowel Cleansing Preparation For Colonoscopies

- Statement Regarding Xifaxan Intellectual Property Litigation

- Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation

- Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity

2016

- Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan^® And Relistor^®

- Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit

- Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor^® Tablets

- Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada

- Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

- Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR